Sign In
Buy SRRK
$44.64
-0.0400 (-0.0895%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
10:33am, Tuesday, 31'st Oct 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed th
Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look
05:44pm, Wednesday, 25'th Oct 2023
The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. D
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
01:32pm, Tuesday, 24'th Oct 2023
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the
Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering
02:16pm, Friday, 13'th Oct 2023
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
Why Scholar Rock Holding Stock Soared Today
04:17pm, Thursday, 12'th Oct 2023
Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an investigatio
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
09:01am, Monday, 25'th Sep 2023
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Progn
Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data
09:13am, Sunday, 27'th Aug 2023
Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a phase 2 trial showed sustained improvement in mot
Scholar Rock to Present at the Jefferies Healthcare Conference
04:05pm, Thursday, 01'st Jun 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
08:00am, Monday, 27'th Feb 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f
Scholar Rock to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 08'th Nov 2022
CAMBRIDGE, Mass.
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
10:03am, Thursday, 20'th Oct 2022
Shares are down 70% thus far in 2022. TOPAZ data update for apitegromab in SMA was encouraging (as reflected in increases in HFMSE and RULM scores).
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
08:30am, Friday, 16'th Sep 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.
